TY - JOUR
T1 - Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
AU - Ninomiya, Soranobu
AU - Hara, Takeshi
AU - Tsurumi, Hisashi
AU - Hoshi, Masato
AU - Kanemura, Nobuhiro
AU - Goto, Naoe
AU - Kasahara, Senji
AU - Shimizu, Masahito
AU - Ito, Hiroyasu
AU - Saito, Kuniaki
AU - Hirose, Yoshinobu
AU - Yamada, Tetsuya
AU - Takahashi, Takeshi
AU - Seishima, Mitsuru
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2011/4
Y1 - 2011/4
N2 - Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.
AB - Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=79955928670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955928670&partnerID=8YFLogxK
U2 - 10.1007/s00277-010-1093-z
DO - 10.1007/s00277-010-1093-z
M3 - Article
C2 - 20938662
AN - SCOPUS:79955928670
SN - 0939-5555
VL - 90
SP - 409
EP - 416
JO - Annals of Hematology
JF - Annals of Hematology
IS - 4
ER -